The Global Intravenous Solutions market has been experiencing steady growth for the past few years. Most of the growth in the global market in 2013 stems from the Americas and the EMEA region, and both of these regions together account for approximately 90 percent of the market share. The APAC region is expected to grow at a faster pace owing to the rapid adoption of intravenous solutions and the increasing awareness among the global population about benefits offered by intravenous solutions. The overall market is expected to grow at a CAGR of 7.88 percent during the forecast period.

关键词：静脉内疗法；药物；营养物；最快路线

查看摘要 索取原文[65页]

关键词：CFDA；药品零售；B2C试点

查看摘要 索取原文[1页]

关键词：中药；国际化；标准

查看摘要 索取原文[1页]

关键词：全球；过敏性皮炎药；市场增长

查看摘要 索取原文[1页]

关键词：阻塞性肺病；用药市场

查看摘要 索取原文[1页]

关键词：新版维生素；用量标准

查看摘要 索取原文[1页]

关键词：泊沙康唑；注射剂；FDA；优先审评

查看摘要 索取原文[1页]

《中国证券报》11月20日报道，国家食品药品监督管理总局发布《关于修订含毒性中药饮片中成药说明书的通知》，要求凡处方中含《医疗用毒性药品管理办法》所收载28种毒性药材的中药饮片中成药品种，或其他已被证明具有毒性、易导致严重不良反应的中药饮片中成药品种，生产企业应注明警示。涉及国家秘密技术的中成药品种若含有毒性中药饮片，则以同样标准修订说明书，相关生产企业应于2013年12月31日前提出修订说明书的补充申请。此外，本次说明书修订不涉及保护期内的国家中药一级保护品种。

关键词：医药行业；要闻综述

查看摘要 索取原文[13页]

The study was designed to identify clinically accessible molecular biomarkers of traumatic brain injury (TBI) prior to definitive clinical diagnosis using high throughput microRNA technology. Specifically, these studies were meant to identify, characterize, and validate microRNA biomarker species whose content in peripheral blood mononuclear cells (PBMC) could help to distinguish TBI cases from the Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) veteran population. During the past years, we conducted a Biomarker Discovery study using a high-throughput Array chip platform and identified 18 candidate TBI small RNA biomarkers. Using independent Q-PCR assays, we confirmed that 13 of these candidate small RNA biomarker species are, indeed, significantly down-regulated in PBMC of TBI compared to non-TBI control veteran cases. Additionally, we used unsupervised clustering analysis and demonstrated that the differential regulation of these small RNA biomarkers in clinically accessible blood cells is capable of distinguishing between TBI and non-TBI OEF/OIF veteran cases. Lastly, we identified a 3-biomarker panel capable of distinguishing TBI from non-TBI control veteran cases with 89accuracy 82selectivity and
78specificity. The majority of TBI cases in our biomarker study were co-morbid with PTSD, and our non-TBI control cases were selected to match for PTSD diagnosis. Thus, our identified panel of 13 small RNA biomarkers likely represents biological indices selective for TBI. During the past year, we recruited 13 new cases (6 TBI and 7 non-TBI cases). Together with the cases recruited in previous years, we currently have a total of 83 cases, comprised of 17 TBI and 66 non-TBI control cases, which are available for Biomarker Validation studies.

关键词：医药；血细胞；创伤性脑损伤；临床医学；创伤性休克；退伍军人

查看摘要 索取原文[20页]

The research the National Cancer Institute (NCI) supports, both in our own laboratories and at institutions worldwide, is focused on the ultimate goal of helping cancer patients. That mission achieved through rigorous science extends to NCIs program on complementary and alternative medicine, also known as CAM. Among the highlights of NCIs CAM-related activities in fiscal year (FY) 2010, was the collaboration between NCI, the National Institutes of Healths Office of Dietary Supplements (ODS), and the National Center for Complementary and Alternative Medicine (NCCAM) to co-fund two Botanical Research Centers. The Botanical Research Centers Program aims to promote collaborative, integrated, interdisciplinary study of botanicals, particularly those found as ingredients in dietary supplements, and to conduct research with high potential for being translated into practical benefits for human health.

关键词：医药；医学研究；癌症；治疗；疾病防治

查看摘要 索取原文[77页]